← Back to Clinical Trials
Recruiting NCT05009771

NCT05009771 Postoperative Pain Management of Caesarean Section

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05009771
Status Recruiting
Phase
Sponsor Mackay Memorial Hospital
Condition Postoperative Pain
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2022-02-23
Primary Completion 2026-04-30

Eligibility & Interventions

Sex Female only
Min Age 20 Years
Max Age 40 Years
Study Type OBSERVATIONAL
Interventions
Intravenous patient-control analgesiaDinalbuphine sebacate

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2022-02-23 with a primary completion date of 2026-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Caesarean section is one of the most frequent surgeries causing severe postoperative pain. Poor management of acute pain can contribute to postoperative complications, late recovery and the development of chronic pain. Moreover, it had been demonstrated that the intensity of postpartum pain is associated with depression. It is imperative to find out appropriate methods of postpartum pain alleviation. Currently, a lot of analgesic drugs and methods have been developed and used in clinical practice, such as patient-controlled analgesia, extended-release analgesics and multimodal analgesia. This prospective cohort study is aimed to investigate the outcome of each postoperative analgesic method used in caesarean section.

Eligibility Criteria

Inclusion Criteria: 1. Aged 20 to 40. 2. Planing to undergo caesarean section with spinal anesthesia. 3. Scheduled to undergo cesarean section between 37 and 40 weeks of gestation. 4. American Society of Anesthesiology Physical Class 1-2. 5. Planing to alleviate postoperative pain with intravenous patient-controlled analgesia or administration of NALDEBAIN. Exclusion Criteria: 1. Not willing to provide informed consent. 2. Unable to receive opioids or NSAIDs due to contraindication. 3. Long-term use of opioids or drug abuse. 4. Suffering from chronic pain disease. 5. Having medical history of mental illnesses. 6. Diagnosed with Pre-eclampsia or eclampsia. 7. Diagnosed with gestational diabetes. 8. Unsuitable for participation judged by investigator.

Contact & Investigator

Central Contact

Chi-Hsu Wang, M.D.

✉ s871017@gmail.com

📞 +886-2-2809-4661

Principal Investigator

Chi-Hsu Wang, M.D.

PRINCIPAL INVESTIGATOR

MacKay Memorial Hospital Tamsui Branch

Frequently Asked Questions

Who can join the NCT05009771 clinical trial?

This trial is open to female participants only, aged 20 Years or older, up to 40 Years, studying Postoperative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05009771 currently recruiting?

Yes, NCT05009771 is actively recruiting participants. Contact the research team at s871017@gmail.com for enrollment information.

Where is the NCT05009771 trial being conducted?

This trial is being conducted at New Taipei City, Taiwan, Taipei, Taiwan.

Who is sponsoring the NCT05009771 clinical trial?

NCT05009771 is sponsored by Mackay Memorial Hospital. The principal investigator is Chi-Hsu Wang, M.D. at MacKay Memorial Hospital Tamsui Branch. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology